Healthcare stocks are experiencing significant challenges as the sector’s representation in the S&P 500 has declined to its lowest level in decades. The conclusion of earnings season for major biopharmaceutical companies has revealed widespread selloffs, with investor sentiment reaching notably pessimistic levels amid regulatory uncertainties.
According to a recent Goldman Sachs analysis led by Asad Haider, the healthcare sector is grappling with deteriorating performance and growing negative sentiment. Several prominent healthcare companies have faced substantial post-earnings declines, including Vertex Pharmaceuticals, which saw a 20.6% drop on August 4 following setbacks in its pain program. Eli Lilly And Co also experienced its most severe decline since the dot-com era after disappointing results from its oral GLP-1 pill trials.
The turbulence has extended to other major healthcare players, with companies like Novo Nordisk, McKesson Corp, UnitedHealth Group, and Intuitive Surgical all reporting post-earnings drops ranging from 10% to 20%. This earnings season has witnessed unprecedented volatility, with healthcare stocks moving an average of ±6%.
Political and policy considerations are primarily driving the sector’s downturn. The Trump administration’s Most Favored Nation (MFN) pricing proposal for Medicaid and potential pharmaceutical tariffs from ongoing Section 232 investigations have created uncertainty. While the administration’s 100% tariff on chips excludes U.S.-based
manufacturing, pharmaceutical companies are increasing domestic production in response.
Some companies have begun adapting to these challenges. Pfizer has incorporated MFN scenarios into its guidance, while Eli Lilly has expressed openness to gradual price rebalancing between U.S. and EU markets, beginning with new products.
Despite the overall negative trend, some companies have managed to outperform. Johnson & Johnson has demonstrated the strongest post-earnings performance among U.S. pharmaceutical companies and maintains its position as the top year-to-date performer. Gilead Sciences has also shown strength, posting a 6% weekly gain and a 30% year-to-date increase, driven by strong momentum in its HIV franchise and the Yeztugo launch.
The obesity treatment sector has faced particular challenges, with Novo’s profit warning and Eli Lilly’s disappointing oral obesity pill data resulting in a combined market cap loss of $100 billion, though Novo has seen a partial recovery. Wall Street analysts have responded by reducing obesity forecasts and price targets.
Looking ahead, Goldman analyst Salveen Ritcher suggests that while the biotechnology sector has shown some recovery since April lows, with various indices showing modest gains over the past month, continued volatility is likely in the second half of the year. Policy
developments regarding tariffs, tax policy, drug pricing, Medicaid cuts, and FDA/HHS regulations remain critical factors to watch.
The industry awaits potential announcements regarding pharmaceutical tariffs following the conclusion of Section 232 investigations, expected by mid-August. Notably, pharmaceuticals were excluded from the recent US-EU trade deal, which established a 15% baseline tariff rate for most EU imports, pending the investigation’s conclusion.
The current state of healthcare stocks reflects broader market uncertainties and regulatory challenges, with the sector’s diminished S&P 500 weighting indicating a significant shift in market dynamics and investor confidence.